You just read:

Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

News provided by

Blueprint Medicines Corporation

Dec 10, 2017, 07:00 EST